ClinicalTrials.gg
RecruitingNCT05727722Updated Jun 27, 2025

Micro-encapsulated Hepatocyte Intraperitoneal Transplantation in Liver Failure Adults

A Phase 1 interventional study of a single course of micro-encapsulated hepatocytes intraperitoneal transplantation therapy in Acute-On-Chronic Liver Failure and Chronic Liver Failure, sponsored by RenJi Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-06-27.

Sponsored by RenJi Hospital · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Acute-On-Chronic Liver Failure with a site in China — 18 open to participants now, 22 under way, none of them phase 3. Acute-On-Chronic Liver Failure · China.

Planned enrollment
22nd of 25
10 · median 80
Started
2024
with 3 others
Phase 1
5 of 48
2 open now
Primary completion
2025-12
later than 12 of 21 live
Registered
27th of 48
by date
Lead sponsor
2 of 48
RenJi Hospital

Among the 48 studies in Acute-On-Chronic Liver Failure with a site in China, this one is the 22nd largest by planned enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2024, is one of 5 in phase 1, reaches primary completion later than 12 of the 21 other live ones, and was the 27th registered.

Acute-On-Chronic Liver Failure

167 studies on the registry are indexed under Acute-On-Chronic Liver Failure; 61 are open to participants now.

Browse Acute-On-Chronic Liver Failure studies →

Open to participants now

18 of the 48 studies in Acute-On-Chronic Liver Failure with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 32 Acute-On-Chronic Liver Failure studies recruiting now, 11 (34%) set no upper age limit and 15 (47%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Acute-On-Chronic Liver Failure with a site in China, or all of them as a file.
02

Study summary

This is a prospective single-center dose escalation study of the administration of the microencapsulated hepatocyte therapy in adult liver failure. The purpose of the study is to determine the maximum tolerated dose of microencapsulated hepatocytes in liver failure patients and its effectiveness in treating the disease. We previously generated proliferating human hepatocytes (ProliHH) through dedifferentiation of PHH and engineered them into encapsulated liver organoids (eLO), providing an unlimited cell source for hepatocyte transplantation.

Read the detailed description

This study is a single-center unblinded single-arm study comprised of a dose escalation phase and a preliminary assessment of efficacy. Subjects who were diagnosed with liver failure (including chronic liver failure and acute-on-chronic liver failure) received 3 days' regular treatment with no beneficial effect and volunteered to participate in micro-encapsulated hepatocytes intraperitoneal transplantation therapy will be enrolled. Before the clinical research, the recruitment criteria and micro-encapsulated hepatocytes transplantation protocol will be confirmed. To minimize the number of patients receiving unbeneficial therapeutic dosage, the accelerated titration design and "3+3" design will be used to decide the dosage group. All micro-encapsulated hepatocytes transplantation patients will be monitored after 1, 3, 7, 14, 28, and 60 days after treatment for safety and primary efficacy analyses. The patients could still receive regular clinical treatment including liver transplantation.

03

Conditions studied

  • Acute-On-Chronic Liver Failure
  • Chronic Liver Failure

Keywords

  • Acute-On-Chronic Liver Failure
  • Chronic Liver Failure
  • cell transplantation
  • hepatocyte transplantation
  • micro-encapsulate
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A. Chronic liver failure (CLF) group:

The progressive liver function decline or decompensation after liver cirrhosis:

  1. Body weight>40kg;
  2. Aged between 18 to 65 years old;
  3. Serum Total was higher than the normal range and lower than 10 times the value (ULN);
  4. With or without significantly decreased serum albumin value, lower than 35;
  5. With or without significantly decreased (PLT) value, prothrombin activity (PTA)≤40% (or (INR)≥1.5), other reasons excluded;
  6. With or without ascites or portal hypertension;
  7. With or without a stage I or II hepatic encephalopathy;
  8. No obvious improvement after more than 3 days' regular clinical treatments.

OR B. Acute-on-chronic liver failure (ACLF) group:

With known or unknown basic liver diseases, subjects undergoing acute liver failure syndrome (clinical manifestations indicated as an early stage liver failure).

  1. Body weight>40kg;
  2. Aged between 18 to 65 years old;
  3. With obvious fatigue, accompanied by other gastrointestinal symptoms such as anorexia, vomiting, and abdominal distension;
  4. Complicated with ascites and/or hepatic encephalopathy within 4 weeks after being diagnosed;
  5. Progressive aggravation of jaundice, total serum bilirubin≥85umol/L;
  6. Coagulation disorders, INR>1.5 or PTA\<40%;
  7. No obvious improvement after more than 3 days' regular clinical treatments.

Exclusion criteria

Exclusion Criteria:

  1. With obvious brain edema, cerebral hernia, or indicated intracranial hemorrhage;
  2. Diagnosed or suspected as primary or liver cancer;
  3. With uncorrectable oxygenation index (PaO2/FiO2)\<200;
  4. With disseminated intravascular coagulation;
  5. Active hemorrhage;
  6. Uncontrollable infection, including ascites infection such as spontaneous bacterial peritonitis;
  7. Uncorrectable decrease in (\<20×109/L);
  8. and/or SARS-CoV-Ⅱ positive;
  9. Drug abuse within 1 year;
  10. Systemic hemodynamic instability;
  11. Combined with pregnancy or lactation;
  12. Other situations excluded by clinician;
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Micro-encapsulated Hepatocyte Intraperitoneal Transplantation Cohort 1

    Participants will each be administered the dosage of 0.15×10\^9 for one time, with 60 days follow-up after the cell infusion.

    Biological: a single course of micro-encapsulated hepatocytes intraperitoneal transplantation therapy

  • Experimental
    Micro-encapsulated Hepatocyte Intraperitoneal Transplantation Cohort 2

    Participants will each be administered the dosage of 0.5×10\^9 for one time, with 60 days follow-up after the cell infusion.

    Biological: a single course of micro-encapsulated hepatocytes intraperitoneal transplantation therapy

  • Experimental
    Micro-encapsulated Hepatocyte Intraperitoneal Transplantation Cohort 3

    Participants will each be administered the dosage of 1.5×10\^9 for one time, with 60 days follow-up after the cell infusion.

    Biological: a single course of micro-encapsulated hepatocytes intraperitoneal transplantation therapy

  • Experimental
    Micro-encapsulated Hepatocyte Intraperitoneal Transplantation Cohort 4

    Participants will each be administered the dosage of 4.5×10\^9 for one time, with 60 days follow-up after the cell infusion.

    Biological: a single course of micro-encapsulated hepatocytes intraperitoneal transplantation therapy

Interventions

  • Biologicala single course of micro-encapsulated hepatocytes intraperitoneal transplantation therapy

    A single course will be divided into an "accelerated titration design" phase and a "3+3 design" phase to reduce the number of subjects exposed to potentially ineffective doses that may not benefit from treatment. The "accelerated titration design" phase starts at a starting dose of 0.15x10\^9, moving to the "3+3 design" phase at the dose of 0.5x10\^9. According to the semi-logarithmic incremental (10\^0.5-fold) approach, the treatment dosage was set into four groups at a maximum dose of 4.5×10\^9 (allowing for a ±20% difference between the actual dose and the planned dose, considering production specifics). The number or the incremental ratio of subsequent dose groups can be adjusted based on the evaluation of available data in the study, and intermediate doses can be explored.

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse events

    All adverse events are defined and graded following the National Cancer Institute-Common Terminology Criteria for Adverse Events V.5.0. Adverse events (AE), serious adverse events (SAE), and treatment emergent AEs (TEAE)

    Time frame: baseline to 60 days after cell transplantation therapy

  2. Maximum tolerated dose (MTD)

    The maximum tolerated dose (MTD) is defined as the highest dose at which no more than 1 of at least 6 subjects developed dose-limiting toxicity (DLT). During the DLT observation period, another patient should be enrolled if one subject does not complete the DLT observation period due to withdrawal for reasons other than DLT.

    Time frame: baseline to 60 days after cell transplantation therapy

Secondary outcomes

  1. Model for end-stage liver disease (MELD) score system

    Laboratory test results used to calculate the MELD score must be obtained at the same time point, and the results need to be obtained within 6 hours of the blood draw.

    Time frame: baseline to 60 days after cell transplantation therapy

  2. The survival rates compared with historical controls

    The life table method was used to calculate the survival rate of patients.

    Time frame: the 60th day after cell transplantation therapy

  3. Serum antibodies against human leukocyte antigen (HLA) Class I and II

    The serum antibodies against HLA Class I and II are used to for immunogenicity evaluation.

    Time frame: baseline to 60 days after cell transplantation therapy

  4. Incidence of Clinical improvement

    diagnosed refer to Chapter 2.6.2.2 of Guidelines for the Diagnosis and Management of Liver Failure (2018, China).

    Time frame: baseline to 60 days after cell transplantation therapy

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Yang T, Zhu X, Long M, Hui L, Yuan X, Sun Z, Zhang L, Xia Q, Wan P. Phase I safety and tolerability dose escalation study of microencapsulated hepatocyte intraperitoneal transplantation therapy in adult patients with liver failure: a study protocol. BMJ Open. 2025 Apr 15;15(4):e087828. doi: 10.1136/bmjopen-2024-087828. PubMed 40233953 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2024 (actual). Primary completion is estimated for Dec 2025, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2022
First posted
Feb 14, 2023
StartActual
Mar 1, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Feb 28, 2026
Last update
Jun 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05727722
Lead sponsor
RenJi Hospital
Collaborators
Shanghai Institute of Biochemistry and Cell Biology
Responsible party
Sponsor
First posted
Feb 14, 2023
Start date
Mar 1, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Feb 28, 2026 (estimated)
Last update
Jun 27, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion